Kemal Malik
Independent DirectorDr. Kemal Malik, MBBS, serves as Senior Independent Director at Syncona Investment Management Limited from August 2025. He served as Non Executive Director at Syncona Investment Management Limited since June 15, 2020 until August 2025. Dr. Malik is Independent Director of Cartesian Therapeutics, Inc. from July 2024. Dr. Malik has global development, regulatory and commercial expertise at leading pharmaceutical organizations. He serves as Member of Scientific Advisory Board at Atomwise, Inc. since June 2021. He serves as Non Executive Director at Syncona Limited since June 15, 2020. He has been Director of Acceleron Pharma Inc. since January 1, 2020. Dr. Malik has in global pharmaceutical research and development. Dr. Malik was a Member of Management Board at Bayer AG since February 1, 2014 until December 2019 and served as its Head of Innovation. He was also responsible for Bayer LEAPS. Dr. Malik served as the Head of Global Development and Chief Medical Officer at Bayer Pharma AG and served as its Member of Board of Management since February 1, 2007 and was responsible for all development and medical governance issues, where he delivered twenty consecutive positive phase III trials including several blockbusters such as Xarelto® and Eylea®. He served as the Chief Medical Officer, Pharmaceuticals and Head of Global Development at Bayer HealthCare AG since February 1, 2007. Currently, he served as Scientific Adviser to Numerion Labs until October 2026, Adviser to KKR and Trustee of Our Future Health. He joined Bayer in 1995 as Head of Metabolism and Oncology Europe in what was then the Pharmaceuticals Business Group and served as Head of Global Medical Development. He spent several years in clinical medicine at the Northwick Park Clinical Research Centre. He then held various positions of increasing responsibility in medical affairs and clinical development at Bristol-Myers Squibb in the United Kingdom. He has extensive experience in global pharmaceutical research and development. Dr. Malik studied medicine at Charing Cross and Westminster Medical School (Imperial College London) in 1987 and is a Member of the Royal College of Physicians. Dr. Malik received his Bachelor of Medicine, Bachelor of Surgery from the University of London.
公司職務
- 公司名稱Cartesian Therapeutics, Inc.股票代碼RNAC職務Independent Director共事同僚
- CBCarsten BrunnPresident, CEO & Chairman of the Board
- BTBlaine T. DavisChief Financial Officer
- EEEmily EnglishChief Operating Officer
- JSJune SeymourChief Accounting Officer
- CGChar GrossFractional Chief People Officer
- TCTimothy C. BarabeIndependent Director
- PJPatrick J. ZennerLead Independent Director
- MSMichael Scott SingerIndependent Director
